, Situation report: Ebola virus disease. Geneva: World Health Organization, World Health Organization, 2016.
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-ofconcept trial in Guinea, PLoS Med, vol.13, p.26930627, 2016. ,
Experimental treatment of Ebola virus disease with brincidofovir, PLoS ONE, vol.11, p.27611077, 2016. ,
, Multi-National PREVAIL II Study Team. A Randomized, controlled trial of ZMapp for Ebola virus infection, N Engl J Med, vol.375, p.27732819, 2016.
Experimental treatment of Ebola virus disease with TKM-130803: a single-arm phase 2 clinical trial, PLoS Med, vol.13, p.27093560, 2016. ,
Evaluation of convalescent plasma for Ebola virus disease in Guinea, N Engl J Med, vol.374, pp.33-42, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-01252702
, World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. Geneva: World Health Organization, 2015.
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Res, vol.105, p.24583123, 2014. ,
Post-exposure efficacy of oral T-705 (favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Res, vol.104, p.24462697, 2014. ,
Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials, Clin Pharmacokinet, vol.55, p.26798032, 2016. ,
URL : https://hal.archives-ouvertes.fr/inserm-01344917
Implementation of a non-human primate model of Ebola disease: infection of Mauritian cynomolgus macaques and analysis of virus populations, Antiviral Res, vol.140, p.28132865, 2017. ,
Favipiravir pharmacokinetics in Ebola-infected patients of the JIKI trial reveals concentrations lower than targeted, PLoS Negl Trop Dis, vol.11, p.28231247, 2017. ,
Favipiravir pharmacokinetics in nonhuman primates and insights for future efficacy studies of hemorrhagic fever viruses. Antimicrob Agents Chemother, vol.61, p.27736754, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01524308
Dose regimen of favipiravir for Ebola virus disease, Lancet Infect Dis, vol.15, p.25435054, 2015. ,
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.514, p.25171469, 2014. ,
Development and evaluation of a fluorogenic 5 0 nuclease assay to detect and differentiate between Ebola virus subtypes Zaire and Sudan, J Clin Microbiol, vol.39, p.11682540, 2001. ,
Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever, Antiviral Res, vol.121, p.26186980, 2015. ,
T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro, J Virol, vol.87, p.23325689, 2013. ,
Lethal mutagenesis of hepatitis C virus induced by favipiravir, PLoS ONE, vol.11, p.27755573, 2016. ,
Favipiravir can evoke lethal mutagenesis and extinction of foot-and-mouth disease virus, Virus Res, vol.233, p.28322918, 2017. ,
Extinction of West Nile virus by favipiravir through lethal mutagenesis, Antimicrob Agents Chemother, vol.61, pp.1400-1417, 2017. ,
Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase, Antimicrob Agents Chemother, vol.57, p.23917318, 2013. ,
Influenza virus neuraminidase inhibitors, Lancet, vol.355, p.10711940, 2000. ,
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys, Nature, vol.531, pp.381-386, 2016. ,
Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection, Am J Pathol, vol.163, p.14633608, 2003. ,
Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection, J Infect Dis, vol.212, pp.91-98, 2015. ,
Mechanism of action of T-705 against influenza virus, Antimicrob Agents Chemother, vol.49, p.15728892, 2005. ,
Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells, J Antimicrob Chemother, vol.64, p.19643775, 2009. ,
Clinical and virological characteristics of Ebola virus disease patients treated with favipiravir (T-705), Clin Infect Dis, vol.63, p.27553371, 2014. ,
Use of viremia to evaluate the baseline case fatality ratio of Ebola virus disease and inform treatment studies: a retrospective cohort study, PLoS Med, vol.12, p.26625118, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01274833
Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature, vol.521, p.25901685, 2015. ,
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study, Lancet Glob Health, vol.5, p.27955791, 2017. ,
Dynamics of Ebola RNA persistence in semen: report from the Postebogui cohort in Guinea, Clin Infect Dis, vol.64, p.28329169, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01773727
Late Ebola virus relapse causing meningoencephalitis: a case report, Lancet, vol.388, issue.16, p.27209148, 2016. ,
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, Lancet, vol.386, issue.15, p.26248676, 2015. ,
Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in liberia, N Engl J Med, vol.377, p.29020589, 2017. ,
Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara-vectored Ebola vaccines at 1 year, JAMA, vol.317, p.28291882, 2017. ,
Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever, PLoS Negl Trop Dis, vol.8, p.24786461, 2014. ,
Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model for Lassa fever, J Infect Dis, vol.213, pp.934-942, 2016. ,
Zika plasma viral dynamics in nonhuman primates provides insights into early infection and antiviral strategies, Proc Natl Acad Sci U S A, vol.114, p.28765371, 2017. ,